Clinical trial

A simple breath test could evolve breast cancer diagnostics

The University of Southern California (USC) Norris Comprehensive Cancer Center is actively recruiting for a clinical trial that is researching the effectiveness of a breath test for breast cancer diagnostics. The BreathLink device, manufactured by Menssana Research, Inc., captures a two-minute sample of a patient’s breath and provides immediate results on whether there are indications of breast cancer.

Combined with Mammography, a new breath test could raise the effectiveness of...
Combined with Mammography, a new breath test could raise the effectiveness of detecting breast cancer.
Source: shutterstock/Tomas K

If proven effective, the test would be used in conjunction with mammograms to rule out false-positive tests, sparing patients the pain, cost and anxiety of unnecessary biopsies. “Diagnosing breast cancer requires the utmost vigilance, but we need to temper this vigilance with accuracy to prevent unnecessary testing,” said Linda Hovanessian-Larsen, MD, associate professor of clinical radiology and director of Women’s Imaging at the Keck School of Medicine of USC. Larsen is leading the trial at USC Norris and focuses much of her research to improving the accuracy and efficiency of breast cancer diagnostic techniques. “This kind of technology would be a welcome asset to our field, and we are eager to assess the safety and efficacy of this test.”

BreathLink is a non-invasive testing device that collects, concentrates and analyzes the organic compounds in a patient’s breath sample within minutes. Additionally, test results are uploaded to Menssana’s laboratory in New Jersey. While the test cannot diagnose disease, it can indicate if the patient should undergo further testing, which can save time and money while preventing additional emotional distress. Current research is evaluating the device’s effectiveness in lung cancer, breast cancer, heart transplant rejection, radiation exposure and pulmonary tuberculosis. The device is not yet approved by the Food and Drug Administration.

More information about the trial can be found here.

 

Source: Keck Medicine of USC

25.06.2017

Related articles

Photo

News • Lung cancer CT notification

Breast cancer: Keep CALM – and coordinate your screenings

Many women over 50 schedule mammograms for breast cancer but miss out on CT lung cancer screenings they're also eligible for. Targeted outreach coul help change this, a new study shows.

Photo

News • Unintended effects

Telling women that they have dense breasts may do more harm than good

Should women be told about their high breast density as part of mammography screening? While this may sound like an obvious choice, a new study warns of unintended effects.

Photo

News • Appeal for earlier screening approaches

Alarming number of invasive breast cancers in younger women

Breast cancer – including aggressive variants – are surprisingly common in younger women, a new study shows. The findings strengthen the case for earlier, risk-tailored screening, the authors say.

Related products

Subscribe to Newsletter